Rosen Howard B 4
4 · Kala Pharmaceuticals, Inc. · Filed Jun 23, 2023
Insider Transaction Report
Form 4
Rosen Howard B
Director
Transactions
- Award
Common Stock
2023-06-22+7,988→ 11,387 total - Award
Common Stock
2023-06-22+1,100→ 12,487 total - Award
Stock Option (right to buy)
2023-06-22+10,651→ 10,651 totalExercise: $14.56Exp: 2033-06-21→ Common Stock (10,651 underlying) - Award
Stock Option (right to buy)
2023-06-22+2,500→ 2,500 totalExercise: $14.56Exp: 2033-06-21→ Common Stock (2,500 underlying)
Holdings
- 165(indirect: See Footnote)
Common Stock
Footnotes (7)
- [F1]Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026.
- [F2]Includes 11,290 unvested RSUs.
- [F3]Grant of RSUs under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023.
- [F4]Includes 12,390 unvested RSUs.
- [F5]These shares are owned directly by the Rosen/Doherty Revocable Trust Dated 6/11/01 (the "Trust"), and indirectly by Mr. Rosen as co-trustee of the Trust.
- [F6]This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.
- [F7]This option was granted on June 22, 2023 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023.